Cannabis-Related Disorders Differential Diagnoses

1. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmacother. 2009. 23(2):120-40. [QxMD MEDLINE Link].

2. Remnick D. Going the Distance. The New Yorker. Available at http://www.newyorker.com/reporting/2014/01/27/140127fa_fact_remnick?currentPage=all. Accessed: May 25, 2014.

3. O'Brien M. Poll: Majority of Americans Support Efforts to Legalize Marijuana. NBC News. Available at http://www.nbcnews.com/storyline/legal-pot/poll-majority-americans-support-efforts-legalize-marijuana-n17416. Accessed: May 25, 2014.

4. Frosch D. V.A. Easing Rules for Users of Medical Marijuana. The New York Times. Available at http://www.nytimes.com/2010/07/24/health/policy/24veterans.html?pagewanted=1&_r=1. Accessed: July 24, 2010.

5. MacCoun R, Reuter P. Evaluating alternative cannabis regimes. Br J Psychiatry. 2001 Feb. 178:123-8. [QxMD MEDLINE Link].

6. Reinarman C, Cohen PD, Kaal HL. The limited relevance of drug policy: cannabis in Amsterdam and in San Francisco. Am J Public Health. 2004 May. 94(5):836-42. [QxMD MEDLINE Link]. [Full Text].

7. van den Brink W. Forum: Decriminalization of cannabis. Curr Opin Psychiatry. 2008 Mar. 21(2):122-6. [QxMD MEDLINE Link].

8. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007 Feb 13. 68(7):515-21. [QxMD MEDLINE Link].

9. Miller MC, et al. Medical marijuana and the mind. Harvard Mental Health Letter. April 2010. 26:1-4.

10. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012 Jan 11. 307(2):173-81. [QxMD MEDLINE Link].

11. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29. 82(17):1556-63. [QxMD MEDLINE Link]. [Full Text].

12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Washington D.C.: American Psychiatric Association; 2022.

13. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009 Mar. 11(1):109-19. [QxMD MEDLINE Link]. [Full Text].

14. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist?. Br J Pharmacol. 2010 Jun. 160(3):523-9. [QxMD MEDLINE Link]. [Full Text].

15. Ringen PA, Vaskinn A, Sundet K, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med. 2009 Nov 6. 1-11. [QxMD MEDLINE Link].

16. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Available at https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf. 2021; Accessed: May 3, 2022.

17. 2021 Monitoring the Future Survey. National Institute on Drug Abuse. Available at https://nida.nih.gov/drug-topics/trends-statistics/monitoring-future. Accessed: May 3, 2022.

18. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006 Oct. 36(10):1447-60. [QxMD MEDLINE Link].

19. Annual Report 2012: The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Available at http://www.emcdda.europa.eu/attachements.cfm/att_190854_EN_TDAC12001ENC_.pdf.

20. Wilson N, Cadet JL. Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis. 2009 Oct. 28(4):309-19. [QxMD MEDLINE Link].

21. Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, et al. Medicinal THC (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standardized Field Sobriety Tests. Addiction. 2012 May 4. [QxMD MEDLINE Link].

22. Barrigón ML, Gurpegui M, Ruiz-Veguilla M, et al. Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. J Psychiatr Res. 2010 May. 44(7):413-20. [QxMD MEDLINE Link].

23. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010 Aug. 167(8):987-93. [QxMD MEDLINE Link]. [Full Text].

24. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1. 342:d738. [QxMD MEDLINE Link]. [Full Text].

25. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis Use and Earlier Onset of Psychosis: A Systematic Meta-analysis. Arch Gen Psychiatry. 2011 Jun. 68(6):555-61. [QxMD MEDLINE Link].

26. Peter Hecht. Report: African-Americans disproportionately targeted for pot. The Sacramento Bee. Available at http://blogs.sacbee.com/weed-wars/2010/06/report-african-americans-disproportionately-targeted-for-pot.html. Accessed: August 3, 2010.

27. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011 May 1. 115(1-2):120-30. [QxMD MEDLINE Link]. [Full Text].

28. Preuss UW, Watzke AB, Zimmermann J, Wong JW, Schmidt CO. Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend. 2010 Jan 15. 106(2-3):133-41. [QxMD MEDLINE Link].

29. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004 Nov. 161(11):1967-77. [QxMD MEDLINE Link].

30. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011 Dec 1. 119(1-2):123-9. [QxMD MEDLINE Link].

31. Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006 Apr. 28(2):155-63. [QxMD MEDLINE Link].

32. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict. 2009 Jan-Feb. 18(1):53-64. [QxMD MEDLINE Link]. [Full Text].

33. Degenhardt L, Dierker L, Chiu WT, et al. Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend. 2010 Apr 1. 108(1-2):84-97. [QxMD MEDLINE Link]. [Full Text].

34. Agrawal A, Lynskey MT. The genetic epidemiology of cannabis use, abuse and dependence. Addiction. 2006 Jun. 101(6):801-12. [QxMD MEDLINE Link].

35. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis?. Can J Psychiatry. 2006 Aug. 51(9):556-65. [QxMD MEDLINE Link].

36. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009 Dec. 195(6):488-91. [QxMD MEDLINE Link]. [Full Text].

37. Gruber SA, Yurgelun-Todd DA. Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res Cogn Brain Res. 2005 Apr. 23(1):107-18. [QxMD MEDLINE Link].

38. Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005 Aug. 181(1):170-8. [QxMD MEDLINE Link].

39. Hurd YL, Wang X, Anderson V, Beck O, Minkoff H, Dow-Edwards D. Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol. 2005 Mar-Apr. 27(2):221-9. [QxMD MEDLINE Link].

40. Iversen L. Cannabis and the brain. Brain. 2003 Jun. 126(Pt 6):1252-70. [QxMD MEDLINE Link].

41. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2005. Bethesday, MD: National Institute on Drug Abuse;. 2006. NIH Publication No. 06-5882:

42. [Guideline] Kleber HD, Weiss RD, Anton RF, et al. Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry. 2006 Aug. 163(8 Suppl):5-82. [QxMD MEDLINE Link].

43. Ramaekers JG, Moeller MR, van Ruitenbeek P, et al. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 2006 Nov 8. 85(2):114-22. [QxMD MEDLINE Link].

44. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006 Jul 20. 24(21):3394-400. [QxMD MEDLINE Link].

45. Whitcomb D. Marijuana legalization will be on California ballot. Reuters. Available at http://www.reuters.com/article/idUSTRE62O08U20100325. Accessed: July 24, 2010.

46. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006 Apr. 39(4):421-9. [QxMD MEDLINE Link].

Lawrence Genen, MD, MBA Board Certified Psychiatrist; Diplomate, American Board of Psychiatry and Neurology; Founder, The Genen Group - A Multi-Specialty Psychiatry and Psychotherapy Practice

Disclosure: Nothing to disclose.

John Franzen, MD Resident Physician, Department of Psychiatry, University of Nebraska-Creighton University

Disclosure: Nothing to disclose.

William F Haning, III, MD, FASAM, DFAPA Professor of Psychiatry, Director of Graduate Affairs, Office of the Dean, Program Director, Addiction Psychiatry/Medicine, Department of Psychiatry, University of Hawaii, John A Burns School of Medicine; Principal Investigator and Co-Director, Pacific Addiction Research Center

William F Haning, III, MD, FASAM, DFAPA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Addiction Psychiatry, American Medical Association, American Psychiatric Association, American Society of Addiction Medicine, Association of Military Surgeons of the US, Hawaii Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.

Barry I Liskow, MD Professor of Psychiatry, Vice Chairman, Psychiatry Department, Director, Psychiatric Outpatient Clinic, The University of Kansas Medical Center

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Robert C Daly, MB, ChB, MPH, BCh; Can M Savasman, MD; Caroline Fisher, MD, PhD; and Lina Cassandra Vawter, MD to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article